Type I and type IV allergy to insulin detemir

Lancet

Volumn 369, Issue 9577, 2007, Pages 1926-

  Dejgaard, Anders ^a   Larsen, Jens ^a   Pedersen, Christian Ross ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; DRUG DERIVATIVE; INSULIN;

DRUG HYPERSENSITIVITY; HUMAN; INJECTION SITE REACTION; INTRACUTANEOUS TEST; LETTER; LONG TERM CARE; PRIORITY JOURNAL; SKIN MANIFESTATION; CLASSIFICATION; IMMUNOLOGY; NOTE;

DRUG HYPERSENSITIVITY; HUMANS; INSULIN;

EID: 34249883286     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60909-X     Document Type: Letter

References (4)

1. Sola-Gazagnes A., Pecquet C., M'Bemba J., Larger E., and Slama G. Type I and type IV allergy to the insulin analogue detemir. Lancet 369 (2007) 637-638
2. European Medicines Agency. Insulatard: summary of product characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/insulatard/H-441-PI-en.pdf (accessed Feb 28, 2007).
3. European Medicines Agency. Lantus: summary of product characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Lantus/H-284-PI-en.pdf (accessed Feb 28, 2007).
4. European Medicines Agency. Levemir: summary of product characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/levemir/H-528-PI-en.pdf (accessed Feb 28, 2007).